Trump Budget Contains Little on Drug Prices Despite Tough Talk
- President had promised to tackle U.S. drug-pricing issues
- Plan would prod FDA to make changes to benefit drug industry
Trump's Budget Would Dramatically Reduce Govt.'s Role
This article is for subscribers only.
President Donald Trump has repeatedly excoriated pharmaceutical companies for high drug costs, but the policy and spending plans in his administration’s 2018 health budget contain almost no major proposals that would impact the industry’s pricing practices.
On the campaign trail and after taking office, Trump repeatedly criticized the drug industry. He said drugmakers were “getting away with murder” and said he’d have the U.S. government make the industry bid for government business, a dramatic proposition to cut prices that sent biotechnology and drug stocks spiraling downward on more than one occasion.